P53 Immunostaining Distinguishes Malignant from Benign Lesions of the Gall-bladder
Overview
Authors
Affiliations
The expression of p53 protein was studied in formalin-fixed paraffin-embedded specimens of 41 well-differentiated adenocarcinomas of the gall-bladder, six cases of acute cholecystitis and 23 cases of chronic cholecystitis, using a monoclonal p53 (PAb 1801) antibody and streptavidin-biotin. p53 staining was divided into diffuse, focal or sporadic patterns. The relationship between the p53 Labeling Index (p53 LI) and cellular proliferation was also investigated using monoclonal Ki-67 (MIB1) antibody. Twenty-four of the 41 carcinomas (58.5%) had a diffuse staining pattern with a high p53 LI (47-93%) and 9.8% (4/41) had a focal staining pattern with an intermediate p53 LI (22-34%), with no relation to pT stage, tumor size, histologic type or grade of cytologic atypia. The p53 LI was higher than the Ki-67 LI in these tumors except for one. On the other hand, p53 staining was completely sporadic in the non-neoplastic specimens with a low p53 LI (0.2-2.8%). The p53-positive cells in these specimens were located only within areas of Ki-67-positive cells. In conclusion, p53-protein overexpression occurs as an early event in approximately 70% of well-differentiated adenocarcinomas of the gall-bladder, and this alteration is maintained during progression from intramucosal to invasive carcinoma. p53 immunostaining can distinguish malignant from benign lesions of the gall-bladder.
Deregulation of MYC and TP53 through genetic and epigenetic alterations in gallbladder carcinomas.
Ishak G, Leal M, Dos Santos N, Demachki S, Nunes C, Borges B Clin Exp Med. 2014; 15(3):421-6.
PMID: 25200035 DOI: 10.1007/s10238-014-0311-8.
Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor.
Kai K, Masuda M, Ide T, Takase Y, Miyoshi A, Kitahara K Mol Clin Oncol. 2014; 1(4):633-638.
PMID: 24649220 PMC: 3915657. DOI: 10.3892/mco.2013.121.
Ghosh M, Sakhuja P, Singh S, Agarwal A Saudi J Gastroenterol. 2013; 19(1):34-9.
PMID: 23319036 PMC: 3603488. DOI: 10.4103/1319-3767.105922.
Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy.
Funabiki T, Matsubara T, Miyakawa S, Ishihara S Langenbecks Arch Surg. 2008; 394(1):159-69.
PMID: 18500533 DOI: 10.1007/s00423-008-0336-0.
Legan M, Luzar B, Marolt V, Cor A World J Gastroenterol. 2006; 12(21):3425-9.
PMID: 16733863 PMC: 4087877. DOI: 10.3748/wjg.v12.i21.3425.